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Abstract
Background and Aim: Few studies have explored the possible plasma cholesterol lowering effects of rye consumption. The
aim of this secondary analysis in the SYSDIET study was to investigate the association between plasma alkylresorcinols (AR),
a biomarker for whole grain wheat and rye intake, and blood lipid concentrations in a population with metabolic syndrome.
Furthermore, we analyzed the associations between the AR C17:0/C21:0 ratio, a suggested marker of the relative intake of
whole grain/bran rye, and blood lipid concentrations.
Methods: Participants were 30–65 years of age, with body mass index (BMI) 27–40 kg/m2 and had metabolic syndrome.
Individuals were recruited through six centers in the Nordic countries and randomized either to a healthy Nordic diet (ND,
n = 93), rich in whole grain rye and wheat, as well as berries, fruits and vegetables, rapeseed oil, three fish meals per week
and low-fat dairy products, or a control diet (n = 65) for 18/24 weeks. Associations between total plasma AR concentration
and C17:0/C21:0 homologue ratio and blood lipids were investigated in pooled (ND + control group) regression analyses at
18/24 weeks adjusted for baseline value for the dependent variable, age, BMI and statin use.
Results: When adjusted for confounders, total plasma AR at 18/24 weeks was not significantly associated with blood lipids
but the AR ratio C17:0/C21:0 was inversely associated with LDL cholesterol concentrations (B (95% CI): 20.41 (20.80 to 2
0.02)), log LDL/HDL cholesterol ratio (20.20 (20.37 to 20.03)), log non-HDL cholesterol (20.20 (20.37 to 20.03)), log
apolipoprotein B (20.12 (20.24 to 0.00)) and log triglyceride concentrations (20.35 (20.59 to 20.12)).
Discussion: Increased proportion of whole grain rye, reflected by a biomarker, in the diet is associated with favorable blood
lipid outcomes, a relationship that should be further investigated.
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Introduction
Epidemiological studies have shown an inverse relationship
between diets rich in whole grain and the risk of many diet-related
diseases, including cardiovascular diseases [1,2], metabolic syn-
drome [3] and type 2 diabetes [4]. A number of intervention
studies have shown that intake of whole grains lowers serum total
and LDL cholesterol concentrations [5–8], blood pressure [9,10]
and improves insulin sensitivity [11–13]. Animal studies have
shown cholesterol lowering effects of rye consumption [14–16] but
few intervention studies have studied the effects of rye on blood
lipids in humans, despite the fact that whole grain rye products
contain substantial amounts of extractable arabinoxylans and b-
glucans [17] that may contribute to cholesterol reduction. One
study has shown that rye bread consumption decreased total and
LDL cholesterol concentrations in men with moderately elevated
serum cholesterol [5] but another study showed an unfavorable
shift in serum cholesterol concentrations after rye bread intake in
postmenopausal women [18].
In nutritional science it is essential to have accurate dietary
information to assess compliance to dietary interventions and to
investigate diet-disease associations. Collecting valid data on whole
grain intake can, however, be challenging due to the broad
selection of foods contributing to these intakes [19]. The use of
alkylresorcinols (AR) as dietary biomarkers for whole grain wheat
and rye intake could improve the validity of dietary assessment of
whole grain in combination with, or as an alternative for, self-
reports [19–22]. It may also be used as a tool for secondary
analysis, where non-compliant individuals can be excluded on the
basis of the biomarker measurements. AR are 3,5-dihydroxy-
phenolic lipids with an odd-numbered alkyl chain generally
ranging from C17 to C25. Among commonly consumed foods,
AR are almost exclusively present in the outer parts of wheat and
rye grains, and just at trace amounts in refined white flour [23,24].
The ratio of the AR homologues C17:0 and C21:0 differs between
cereals but is consistent within cereal species (approximately 0.1 in
wheat and 1 in rye) [24] and may be used to differentiate sources
of cereals consumed via plasma measurements [25]. We have
previously demonstrated that AR are useful biomarkers for whole
grain wheat and rye intake as part of a healthy Nordic diet [26].
Furthermore, significant between-group changes in non-HDL
cholesterol concentrations and LDL to HDL cholesterol ratio was
found in the randomized dietary intervention with a healthy
Nordic diet (SYSDIET) [27].
The present study is based on a secondary analysis of the
SYSDIET intervention trial and the aim was to investigate the
association between plasma AR, a biomarker for whole grain
wheat and rye intake, and blood lipid concentrations in a
population with metabolic syndrome (MetS) participating in a
randomized dietary intervention. Furthermore, the associations
between the AR C17:0/C21:0 ratio, a suggested marker of the
relative whole grain/bran rye intake, and blood lipids were
analyzed.
Methods
The current study was a part of the SYSDIET study, a
randomized controlled multicenter parallel group study with
balanced randomization (1:1) performed in six intervention centers
(Kuopio and Oulu, Finland; Lund and Uppsala, Sweden; Aarhus,
Denmark and Reykjavik, Iceland) examining the health effects of a
healthy Nordic diet (ND) in a population with MetS. The protocol
for this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
All local ethical committees (Research Ethics Committee of the
Hospital District of Northern Savo and Northern Ostrobothnia
Hospital District, Oulu, Finland, Regional Ethical Review Board,
Lund and The Regional Ethical Review Board in Uppsala,
Sweden, Ethical Committee of Aarhus County, Denmark and The
Icelandic Bioethics Committee, Iceland) approved the SYSDIET
study protocol which followed the Helsinki declaration guidelines
and informed written consent was obtained from all participants.
The trial was registered at ClinicalTrials.gov (ClinicalTrials
identifier: NCT00992641, http://clinicaltrials.gov/ct2/show/
NCT00992641?term=NCT00992641&rank=1) in October 2009,
once all local ethical committees had given their approval. The
authors confirm that all ongoing and related trials for this
intervention are registered.
The study design, inclusion and exclusion criteria, study diets,
the main measurements and analyses performed at each time
point and main results have previously been reported in detail
[27]. The present study is a secondary analysis where the
association between AR and blood lipids at the end of the
intervention was examined.
Study participants
Participants in the study were primarily recruited through
advertisements in newspapers, but also from previous clinical or
epidemiological trials. In brief, the inclusion criteria were age 30–
65 years, body mass index (BMI) 27–40 kg/m2, and two
diagnostic criteria for metabolic syndrome as outlined by the
International Diabetes Federation [28], except type 2 diabetes.
Study design
Participants were randomly assigned to either a healthy Nordic
diet or an average Nordic (control) diet for 18 or 24 weeks. Due to
financial and logistic reasons the study period was 18 weeks at 4
centers (Aarhus, Uppsala, Reykjavik and Oulu) and 24 weeks at 2
centers (Lund and Kuopio) where the intervention was initiated
earlier [27]. The major visits to the study clinics were on week 0
(baseline), week 12 and week 18/24. In Kuopio and Lund, the
intervention was carried out from October 2009 to June 2010, in
Aarhus, from January 2010 to September 2010, in Oulu, from
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December 2009 to October 2010, in Reykjavik, from March 2010
to October 2010 and in Uppsala, from June 2010 to November
2010.
The randomization was done by staff in each study center as
described elsewhere [26]. The staff in all study centers was trained
to perform measurements in a similar way and the quality
management protocol was available for all staff members. The
allowed weight change during the study was aimed to be less than
64 kg due to the isocaloric design applied.
Study diets
The study diets were planned to be isocaloric. Nordic nutrition
recommendations formed the basis of the diet in the ND group
[29] and the mean nutrient intake in the Nordic countries formed
the basis for the control diet. Participants in the ND group were
advised to consume$25% of total energy as whole grain, of which
$50% was comprised of rye, barley and oat which included $6
slices/day of bread with $6 g fiber/100 g (one slice equals 30–
40 g of bread). Participants in the control group were asked to
consume $25% of energy as refined grain, of which $90% made
from wheat. Furthermore, the participants in the ND group were
encouraged to consume $500 g of fruits, vegetables and berries
daily, use rapeseed and/or sunflower and/or soybean oil based
margarines, choose low fat milk and dairy products, consume
three fish meals a week, choose low fat meat, and to avoid sugar-
sweetened beverages while the control group was advised to keep
their habitual diet. Key food products were provided to the study
participants in both groups. The individuals in the ND group
received whole grain products such as oatmeal and barley, crisp
breads, whole grain wheat and rye breads. The individuals in the
control group received low fiber cereal products, e.g. breads with
fiber content less than 6 g/100 g and ordinary pasta. The study
diets have previously been described in detail [27].
The participants were instructed by a clinical nutritionist or a
dietitian at all study visits. The study participants kept dietary
records regarding the intake of cereal products. These records
were checked at each visit to the study center, including the visits
when the groceries were delivered to the participants, i.e. at 1–2
week intervals and the subjects also returned 4-day weighed food
records at baseline, week 2, 12 and 18/24 [27].
Biochemical measurements
Blood samples were collected at week 0, 12 and 18/24.
Automated clinical chemistry analyzers and routine clinical
chemistry methods were used to measure concentrations of total
and HDL cholesterol, triglycerides and apoplipoproteins A1 and
B. The equipment and system reagents and CV%’s have been
described previously [27]. LDL cholesterol concentrations were
calculated using Friedewald’s formula.
Determination of AR in plasma samples were made in
collaboration with the HELGA-Centre at Department of Food
Science, BioCenter at Swedish University of Agricultural Sciences.
A gas chromatography mass spectrometry (GC-MS) method was
used to quantify AR homologues C17:02C25:0 in 0.2 ml plasma
samples as described previously [30]. Quality control samples
(n = 4) was included in each batch to ensure appropriate within-
and between batch precision (CV ,15%). Samples from each
subject were analyzed within the same batch and samples from
different centers were allocated randomly between batches.
Data pooling and statistical analysis
All intervention centers entered their data into Microsoft Office
Excel 2007 (Windows) data form prior to pooling the data in a
joint database maintained at VTT Technical Research Centre of
Finland. Data was exported from the database and imported to
SPSS (Statistical Package for the Social Sciences) for Windows,
version 20.0 (SPSS Inc., Chicago, Illinois, USA) for statistical
analysis. Level of significance in all analyses was set at P,0.05.
Normality of variables was checked by inspection and by using
the Kolmogorov–Smirnov test. Values are described as means and
standard deviations (SD) if normally distributed or as medians and
interquartile range (IQR) if not normally distributed.
The analyses were performed with data from the ND and
control groups combined and associations between total AR and
the AR C17:0/C21:0 ratio at 18/24 weeks and various blood lipid
outcomes were analyzed. Where distributions were skewed (every
variable except total and LDL cholesterol concentrations), log-
transformation was performed on dependent variables for linear
regression to better approximate normal distribution. The
distribution of AR C17:0/C21:0 ratio across total plasma AR
was checked by inspection.
Linear regressions for fasting concentrations of total, LDL,
HDL, non-HDL cholesterol, apolipoproteins A1 and B, triglycer-
ides and LDL/HDL cholesterol ratio with total plasma AR or AR
C17:0/C21:0 ratio (model 1), baseline value for the dependent
variable, age, BMI and statin use, as factors were performed. As
rye often contains more AR than wheat, total plasma AR was
added as a variable, in addition to the variables in model 1 when
the associations between AR C17:0/C21:0 ratio was examined, to
prevent confounding of high AR content (model 2). To account for
multiple testing, we used the Bonferroni correction approach,
using a significance level of alpha divided by the number of
independent outcomes, that is 0.05/8 = 0.006. Furthermore, we
individually adjusted for saturated fat intake calculated from food
records and serum phospholipid fatty acids myristic acid, palmitic
acid, omega-3 fatty acids and C15:0, to prevent confounding of
dietary fat intake.
Results
Altogether 166 participants finished the study and of those 158
subjects had blood samples for AR and blood lipid analyses from
all time points and that group was used for analyses in the present
study (Figure 1). There was no difference between dropouts and
those who completed the study in baseline BMI (P = 0.797), waist
circumference (P = 0.228), age (P = 0.959) or triglyceride
(P = 0.055), total cholesterol (P = 0.743), HDL cholesterol
(P = 0.216) or LDL cholesterol (P = 0.686) concentrations.
There was no change in total energy intake during the study
and energy intake was not different between the groups, hence,
body weight remained constant during the intervention in both
groups. The mean age of the participants was 54.5 (8.2) years,
body weight 91.2 (13.5) kg, BMI 31.7 (3.2) kg/m2 and waist
circumference 104.3 (9.7) cm as described previously [31].
Baseline lipid concentrations and the number of statin users in
by intervention group, are shown in Table 1. The prevalence of
MetS was 90%. No differences were observed between the groups
at baseline in clinical characteristics.
There were small, but significant, decrease in concentrations of
total cholesterol (5.1 (1.2) mmol/L at 18/24 weeks, P = 0.018),
LDL (3.2 (1.1) mmol/L at 18/24 weeks, P = 0.006) and non-HDL
cholesterol (3.8 (1.3) mmol/L at 18/24 weeks, P = 0.006) and
LDL/HDL cholesterol ratio (2.3 (1.3) at 18/24 weeks, P = 0.003)
within the ND group from week 0 to 18/24 but not within the
control group. Results on the effects of the SYSDIET intervention,
with ND, on blood lipid concentrations and other health outcomes
have been reported previously [27]. Both total plasma AR
concentration and the ratio of C17:0/C21:0 were significantly
Plasma Alkylresorcinols Homologue Ratio and Blood Lipids
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higher in the ND group than in the control group at 18/24 week
(Table 2) and the range of total plasma AR was 14 to 499 nmol/L.
There was no skew towards higher AR C17:0/C21:0 ratios for
higher total plasma AR concentrations.
All participants (both ND and control groups) were combined
for secondary analyses on the associations between AR and blood
lipids concentrations at 18/24 weeks. Total plasma AR concen-
tration at 18/24 weeks was not significantly correlated with
concentrations of fasting serum total cholesterol (P = 0.95), LDL
cholesterol (P = 0.23), HDL cholesterol (P = 0.25), LDL-C/HDL-
C ratio (P = 0.13), triglycerides (P = 0.14), apolipoprotein A1
(P = 0.09) or apolipoprotein B (P = 0.86) after adjusting for
Figure 1. Flow chart of the study.
doi:10.1371/journal.pone.0110827.g001
Table 1. Baseline blood lipid concentrations and statin use of the participants.
ND group Control group
(n = 93) (n = 65)
Total cholesterol, mmol/L 5.3 (1.2) 5.1 (1.5)
HDL cholesterol, mmol/L 1.4 (0.5) 1.3 (0.6)
LDL cholesterol, mmol/L 3.2 (1.1) 3.1 (1.5)
Non-HDL cholesterol, mmol/L 3.9 (1.3) 3.7 (1.6)
LDL-C/HDL-C 2.5 (1.4) 2.4 (1.8)
Triglycerides 0 min, mmol/L 1.3 (0.8) 1.4 (0.8)
Apolipoprotein A1, g/L 1.4 (0.3) 1.4 (0.3)
Apolipoprotein B, g/L 1.0 (0.4) 1.0 (0.4)
Statin use, n 19 18
Values are presented as medians (IQR).
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
doi:10.1371/journal.pone.0110827.t001
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confounders. However, the AR C17:0/C21:0 ratio, which reflects
the proportion of whole grain rye of whole grain rye and whole
grain wheat combined, was inversely associated with LDL
cholesterol concentration when adjusted for baseline LDL
cholesterol concentration, BMI, age and statin use (model 1,
P = 0.040) and also when total plasma AR was added to the
regression model (model 2, P = 0.046) (Table 3).
Table 2. Dietary fiber intake, total plasma alkylresorcinols (AR) concentration and AR C17:0/C21:0 ratio for the healthy Nordic diet
group (ND) and control group at baseline and after the 18/24 week intervention.
ND group (n = 93) Control group (n = 65)
Week 0 Week 18/24 Week 0 Week 18/24
Dietary fiber intake1,2, g/day 21.1 (8.8) 36.0 (15.1)# 20.0 (7.1) 16.0 (6.2)*#
Total plasma AR1, nmol/L 73 (88) 106 (108)# 71 (70) 61 (40)*#
C17:0/C21:0 ratio1 0.360.2 0.360.2 0.360.2 0.260.2*#
Values are medians (IQR).
*significantly different from ND group at that time point.
#significantly different from baseline.
1Data published previously [31].
2n = 140, ND group n= 80 and control group n = 40.
Abbreviations: ND, healthy Nordic diet; AR, alkylresorcinols.
doi:10.1371/journal.pone.0110827.t002
Table 3. Regression models for concentrations of serum total, HDL, LDL, non HDL cholesterol and triglycerides and the cholesterol
LDL-C/HDL-C ratio.
Dependent variable at 18/24 weeks Independent variable at 18/24 weeks B1 (95% CI)
Total cholesterol
Model 1 AR C17:0/C21:0 20.33 (20.78 to 0.12)
Model 2 AR C17:0/C21:0 20.33 (20.78 to 0.12)
LDL cholesterol
Model 1 AR C17:0/C21:0 20.41 (20.80 to 20.02)
Model 2 AR C17:0/C21:0 20.40 (20.79 to 20.01)
Log HDL cholesterol
Model 1 AR C17:0/C21:0 0.11 (0.00 to 0.21)
Model 2 AR C17:0/C21:0 0.11 (0.00 to 0.21)
Log LDL-C/HDL-C cholesterol
Model 1 AR C17:0/C21:0 20.20 (20.37 to 20.03)
Model 2 AR C17:0/C21:0 20.20 (20.37 to 20.03)
Log non HDL cholesterol
Model 1 AR C17:0/C21:0 20.84 (21.22 to 20.45)
Model 2 AR C17:0/C21:0 20.81 (21.19 to 20.44)
Log triglycerides
Model 1 AR C17:0/C21:0 20.35 (20.59 to 20.12)
Model 2 AR C17:0/C21:0 20.37 (20.60 to 20.13)
Log apolipoprotein A1
Model 1 AR C17:0/C21:0 0.05 (20.03 to 0.13)
Model 2 AR C17:0/C21:0 0.05 (20.03 to 0.13)
Log apoliprotein B
Model 1 AR C17:0/C21:0 20.12 (20.24 to 0.00)
Model 2 AR C17:0/C21:0 20.12 (20.24 to 0.00)
1B reflects the change in the log-transformed outcome variable for each 1-unit changes in the independent variable.
Model 1: adjusted for baseline value of the dependent variable, BMI, age and statin use.
Model 2: adjusted for baseline value of the dependent variable, total AR, BMI, age and statin use.
Abbreviations: ND, healthy Nordic diet; AR, alkylresorcinols; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index.
doi:10.1371/journal.pone.0110827.t003
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Similarly, AR C17:0/C21:0 ratio was inversely associated with
LDL/HDL cholesterol ratio (P = 0.020 and P = 0.024 for model 1
and model 2, respectively), non-HDL cholesterol (P,0.001 for
both model 1 and model 2), triglyceride (P = 0.004 and P = 0.002
for model 1 and model 2, respectively) and apolipoprotein B
concentrations (P = 0.047 for both model 1 and model 2) and
positively associated with HDL cholesterol concentration
(P = 0.044 and P = 0.049 for model 1 and model 2, respectively).
Including saturated fatty acids calculated from food records to the
models did not change the results nor did including the serum
phospholipid fatty acids myristic acid, palmitic acid, omega-3 fatty
acids and C15:0, except for HDL cholesterol in which the
association with C17:0/C21:0 became borderline significant
(P = 0.067). However, using the Bonferroni correction approach
to account for multiple testing the associations for LDL
cholesterol, HDL cholesterol, LDL/HDL cholesterol ratio and
apolipoprotein B concentrations would not be considered signif-
icant while associations for non-HDL cholesterol and triglyceride
concentration are robust for this correction (P,0.006).
Discussion
Favorable changes in serum LDL cholesterol concentration and
LDL to HDL cholesterol ratio were observed in participants
consuming a healthy Nordic diet, established with a healthy
dietary pattern approach, and thus also rich in whole grain cereals,
for either 18 or 24 weeks [27]. In the intervention the participants
in the ND group were advised to consume $25% of total energy
as whole grain, of which $50% was comprised of rye, barley and
oat, and to make favorable changes in dietary fat intake, and
therefore a change in serum cholesterol concentration in the ND
group was expected. Some studies have found that whole grain
diets lower serum total and LDL cholesterol concentrations [5–8].
The cholesterol lowering effects of b-glucans in oats and barley
have been extensively studied [32,33] and the European Food
Safety Authority (EFSA) has approved two health claims on the
subject: b-glucans contribute to the maintenance of normal blood
cholesterol levels [34] and oat b-glucan has been shown to lower/
reduce blood cholesterol. Blood cholesterol lowering by increased
oats intake may reduce the risk of (coronary) heart disease [35].
In the present study, both ND and control groups were pooled
for secondary analysis on the association between plasma AR and
blood lipids at 18/24 weeks. Plasma AR has been established as a
biomarker for whole grain wheat and rye intake [19,21,26] and
has previously been studied regarding associations with BMI and
metabolic risk factors [36,37]. We observed no association
between total plasma AR concentration and serum lipid concen-
trations, possibly due to a considerable amount of AR intake
originating from whole grain wheat. Whole grain wheat intake
does typically not affect blood cholesterol and is thus often used as
a control in experimental studies [38]. Interestingly, the AR
C17:0/C21:0 ratio, an indicator of relative rye intake, was
associated with favorable changes in concentrations of LDL-,
HDL-, and non HDL cholesterol, LDL/HDL cholesterol ratio
and triglycerides, even after adjustment for fatty acids composition
of serum phospholipids, with the exception of HDL cholesterol
where the association became borderline significant. The ratio of
the AR homologues C17:0 and C21:0 differs between cereal
species and can be used to differentiate between the whole grain
sources in food products [24]. The ratio of AR C17:0/C21:0 is
approximately 0.1 in wheat and 1 in rye and the ratio is to some
extent reflected in fasting plasma samples, although it is generally
lower, typically around 0.6–0.8 in fasting samples after a whole
grain rye intervention for 1–8 weeks, and can be used to
differentiate which AR containing cereals have been consumed
[25,39,40].
Health effects of rye are far less studied than oats and barley and
studies on the effects of rye consumption on cholesterol are scarce.
The mechanisms that have been proposed to cause the reduction
in plasma cholesterol levels focus on the fiber and phytochemical
content of whole grains, particularly water-soluble viscose fiber
[41,42], and it has been established that the cholesterol lowering
effect of b-glucans is dependent on the molecular weight and
subsequent viscosity [43]. Rye is particularly high in dietary fiber,
ranging between 18–22%, and it contains substantial amounts of
extractable b-glucans and arabinoxylans, which could contribute
to cholesterol reduction through a similar mechanism as b-glucans
from oats and barley [17,44]. Animal studies have shown that rye
could affect blood lipid concentrations by increasing the total
concentration of bile acids in the bile [14–15].
Previous studies have shown that rye bread consumption
decreases total and LDL cholesterol concentrations in men with
moderately elevated serum cholesterol [5], and lower concentra-
tions of plasma free-cholesterol, total cholesterol, triglycerides and
phospholipids have been demonstrated after a high fiber rye diet
than a low fiber wheat diet [6]. Additionally, animal studies have
shown cholesterol lowering effects of rye consumption [14–16].
However, Moazzami et al showed an unfavorable shift in serum
cholesterol levels after rye bread intake in postmenopausal women
[18]. Processing of rye and other whole grains, such as
fermentation, have been reported to influence the molecular
weight of cereal dietary fiber, hence it is possible that lower
viscosity of the fibers could explain the lack of beneficial effects
reported in some studies [17]. Nevertheless, the results of the
present study suggest that whole grain rye consumption is
associated with favorable outcomes in blood lipids and this
association should be further studied.
One of the strengths of the present study is that we used AR as a
dietary biomarker for whole grain rye and wheat intake instead of
self-reported estimates. As collecting valid data on whole grain
intake can be challenging, the use of biomarkers to assess intake
and/or compliance to dietary interventions is a way to avoid some
of the obstacles associated with self-reporting [19]. Previously, we
have demonstrated that AR is a good biomarker for the ND under
intervention conditions with moderate to good reliability [26] and
our data supports the use of the AR C17:0/C21:0 ratio as an
indicator for whole grain rye intake in intervention studies where a
diet rich in whole grain rye is being investigated [31]. Although the
AR C17:0/C21:0 ratio reflects only the relative whole grain/bran
rye consumption of total whole grain wheat and rye intake, and
not the total rye intake, the advised whole grain rye intake in the
present study was high in relation to other sources of AR and
therefore the ratio should reflect the total rye intake reasonably
well. However, the present study does not offer any mechanistic
explanations behind the possible cholesterol-lowering by whole
grain rye, and more needs to be done to explain the association.
Nevertheless, the results do motivate further research on this topic.
Some confounding effects from oats intake are possible, as
participants consuming more rye might also consume more oats,
and confounding effects from other food sources cannot be
excluded. However, this is probably not explaining the main
results. Previous studies suggest that plasma AR may be
transported in VLDL and HDL [45], which could affect the
results of the present study, as well as numerous dietary and non-
dietary factors potentially influencing biomarker concentrations
[19]. Nevertheless, since the AR C17:0/C21:0 ratio, but not total
plasma AR, was associated with cholesterol concentrations, and
the associations did not change when adjusted for total plasma
Plasma Alkylresorcinols Homologue Ratio and Blood Lipids
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AR, we believe our findings indicate that the associations we found
are related to whole grain rye intake and not by the fact that AR
may be transported in certain lipoproteins.
Conclusion
Our findings suggest that a greater proportion of whole grain
rye in a Nordic diet is associated with favorable outcomes in blood
lipid concentrations, an association that warrants further investi-
gation.
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